Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab Induction Therapy in Moderately to Severely Active Crohn's Disease
2016-003123-32Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Risankizumab induction with Placebo induction (2 arms). Primary endpoints: Clinical remission at Week 12 and Endoscopic response at Week 12. Started May 2017; status: completed.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2016-003123-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003123-32.